During Open Access Week 2020 and one year after the launch of the Open Pharma position statement on open access, we bring together stakeholders from different backgrounds to share their perspectives on open access publishing of pharma-sponsored research.
Featuring the launch of the Open Pharma position statement on open access, an introduction to the Open Science in Action Inaugural Symposium and a call to action for the UK government to do more to ensure transparent clinical trial reporting.
ORCID is part of the wider digital infrastructure needed for researchers to share information on a global scale. ORCID enables transparent and trustworthy connections between researchers, their contributions, and affiliations by providing an identifier for individuals to use with their name as they engage in research, scholarship and innovation activities. The Open Pharma community is … Continue reading Guest post: ORCID adoption in the pharma community
Featuring the release of the AMWA-EMWA-ISMPP position statement on predatory publishing, the hidden disclosures of medical journal editors, the citation advantage of preprints and the launch of the Open Pharma Calendar of Open Access Events
Featuring the lack of transparency across clinical trials in French hospitals, the introduction of Registered Reports, the data detective who protects patients and one patient advocate’s experience with the medical publishing process
Evidence is essential for identifying treatment priorities and developing polices, said Claire Allen of Evidence Aid, at Evidence-Based Medicine Live (EBMLive), which took place on 15–17 July in Oxford, UK.